• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Expert Opinion on P2Y12 Inhibitors Use in Management of Acute Coronary Syndromes: Focus on Ticagrelor
In conclusion, ticagrelor (180 mg, 90 mg, and 60 mg doses), a potent antiplatelet is expected to reshape the antiplatelet use in the management of ACS.PMID:34781659
Source: Journal of the Association of Physicians of India - November 16, 2021 Category: General Medicine Authors: Immaneni Sathyamurthy M S Hiremath Jitendra Pal Sawhney Subhash Chandra Hrudanand Mishra C K Ponde Shuvanan Ray Suhas Hardas Sunil Sathe P C Rath Bagirath R Girish B Navasundi Vilas Magarkar C N Makhale Suvro Banerjee P R Vaidyanathan Amal Kanti Sen Pande Source Type: research

Clinical Characteristics of Pediatric Patients with Congenital Erythrocytosis: A Single-Center Study
AbstractAlthough congenital erythrocytosis (CE), an inherited disorder, impairs pediatric quality of life, physicians often overlook high hemoglobin (Hgb) levels and its symptoms due to lack of knowledge of age-adjusted pediatric Hgb levels and CE ’s rarity. In a retrospective, single-center study, data from hospital records of pediatric patients diagnosed with CE were evaluated. Twenty-six patients from 25 families (80.8% male) had been diagnosed with CE in 20 years, at a mean age of 14.9 ± 2.8 years (8.3–17.8) and with a mean Hgb level of 17.36 ± 1.44 g/dL (14.63–22.1). No serum erythropoietin levels e...
Source: Indian Journal of Hematology and Blood Transfusion - August 25, 2021 Category: Hematology Source Type: research

Efficacy and safety of ticagrelor versus clopidogrel with different dosages in acute coronary syndrome patients with high GRACE and CRUSADE scores
CONCLUSIONS: In PCI patients with a high ischemic and bleeding risk, the ticagrelor antiplatelet strategy significantly reduced the MACCE rate without increasing the risk of major bleeding. A decreased MACCE rate was also observed in patients administered the double dosage of clopidogrel, but the bleeding risk was increased compared with the control group.PMID:34154742 | DOI:10.1016/j.ihj.2021.02.002
Source: Indian Heart J - June 22, 2021 Category: Cardiology Authors: Peng Xiao Feng Xie Yunjing Lan Source Type: research

Pages: 1  2  3  4  5  6  7  8  9